Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ACCOMPLISH (diabetic subgroup), 2010 - benazepril + amlodipine vs benazepril + hydrochlorothiazide

ACCORD blood pressure, 2010 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ROADMAP, 2010 - olmesartan vs placebo

AVOID, 2008 - aliskiren vs placebo

ADVANCE, 2007 - perindopril and indapamide vs placebo

ABCD (N), 2002 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril vs chlorthalidone

LIFE (diabetic subgroup), 2002 - losartan vs atenolol

ALLHAT (amlodipine vs chlor, diabetic subgroup), 2002 - amlodipine vs chlorthalidone

IPDM, 2001 - irbesartan vs placebo

IDNT amlodipine, 2001 - amlodipine vs placebo

RENAAL, 2001 - losartan vs placebo

IDNT irbesartan, 2001 - Irbesartan vs placebo

IDNT (irbesartan vs amlodipine), 2001 - Irbesartan vs amlodipine

STOP-2 CCB (diabetic subgroup), 2000 - calcium-channel blocker vs diuretic or beta-blocker

INSIGHT (diabetic subgroup), 2000 - Nifedipine vs coamilozide

ABCD (H), 2000 - more intensive blood pressure lowering strategie vs less intensive blood pressure lowering strategie

NORDIL (diabetic subgroup), 2000 - Diltiazem vs diuretic or beta-blocker

STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor vs CCB

HOPE (diabetic subgroup), 2000 - ACE inhibitor vs placebo

STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor vs diuretic or beta-blocker

CAPP (diabetic subgroup), 1999 - captopril vs diuretic or beta-blocker

Syst-Eur (diabetic subgroup), 1999 - nitrendipine vs placebo

ABCD, 1998 - nisoldipine vs enalapril

UKPDS 38, 1998 - captopril or atenolol vs control



See also:

  • All diabetes clinical trials
  • All hypertension clinical trials
  • All clinical trials of anti hypertensive agent
  • All clinical trials of ACE inhibitor
    		•  

    STOP-2 (ACEI vs CCB) (diabetic subgroup) study, 2000

    Facebook    pdf : ACE inhibitor - anti hypertensive agent for hypertension

    Treatments

    Studied treatment ACE inhibitor
    enalapril 10 mg or lisinopril 10 mg daily. if the target blood pressure (<160/95 mm Hg) had not been reached at the 2-month visit or later, patients were given hydrochlorothiazide 12�5�25�0 mg
    Control treatment calcium antagonists
    felodipine 2�5 mg or isradipine 2�5 mg daily. if the target blood pressure (<160/95 mm Hg) had not been reached at the 2-month visit or later patients were given any of the b-blockers in the doses listed

    Patients

    Patients diabetic (subgroup) elderly patients aged 70-84 years
    Inclusion criteria hypertension (blood pressure >=180 mm Hg systolic, >=105 mmHg diastolic, or both); aged 70�84 years; isolated systolic hypertension could be included
    Remarks Of all 6614 patients included in the trial, 719 had diabetes
    Baseline characteristics
    Glycosylated hemoglobin 7.6% 
    BP (systolic/diastolic) 195/96 mmHg 
    Female (%) 60% 
    Age 75.8 y 
    subgroup yes 
    hypertension (%) 100% 

    Method and design

    Randomized effectives 235 / 231 (studied vs. control)
    Blinding open with blind assessment
    Follow-up duration 5.03y
    Number of centre 312
    Geographic area Sweden
    Primary endpoint cardiovascular mortality
    Remarks


    Results



    Endpoints and data reported in the trial's publication(s)

    Endpoint Events (%) Relative Risk 95% CI
    Studied treat. Control treat.
    Cardiovascular mortality 39 / 235 (16,6%) 33 / 231 (14,3%) 1,16 [0,76;1,78]
    Fatal myocardial infarction 4 / 235 (1,7%) 7 / 231 (3,0%) 0,56 [0,17;1,89]
    Fatal stroke 5 / 235 (2,1%) 8 / 231 (3,5%) 0,61 [0,20;1,85]
    Sudden death 11 / 235 (4,7%) 11 / 231 (4,8%) 0,98 [0,43;2,22]
    Other cardiovascular mortality 19 / 235 (8,1%) 7 / 231 (3,0%) 2,67 [1,14;6,23]
    All myocardial infarction 17 / 235 (7,2%) 32 / 231 (13,9%) 0,52 [0,30;0,91]
    All stroke 34 / 235 (14,5%) 29 / 231 (12,6%) 1,15 [0,73;1,83]
    All major cardiovascular events 67 / 235 (28,5%) 69 / 231 (29,9%) 0,95 [0,72;1,27]
    Total mortality 56 / 235 (23,8%) 50 / 231 (21,6%) 1,10 [0,79;1,54]
    Atrial fibrillation 18 / 235 (7,7%) 24 / 231 (10,4%) 0,74 [0,41;1,32]
    Congestive heart failure 22 / 235 (9,4%) 24 / 231 (10,4%) 0,90 [0,52;1,56]

    Endpoints used by the meta-analysis and data retained for this trial

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    cardiovascular event (fatal and non fatal)

    NA / 235
         NA / 253
         0,94 [0,67;1,32]

    Cardiovascular death

    NA / 235
         NA / 253
         1,19 [0,75;1,89]

    All cause death

    NA / 235
         NA / 253
         1,14 [0,78;1,67]

    stroke (fatal and non fatal)

    NA / 235
         NA / 253
         1,16 [0,71;1,90]

    myocardial infarction (fatal and non fatal)

    NA / 235
         NA / 253
         0,51 [0,28;0,92]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.

    Meta-analysis of all similar trials:

    angiotensin renin system blockade in diabetes for all type of patients

    anti hypertensive agent in diabetes for type1 and 2 diabetic patients with hypertension

    anti hypertensive agent in hypertension for diabetic patients



    Reference(s)

    Trials register # NA
    • Lindholm LH, Hansson L, Ekbom T, Dahl�f B, Lanke J, Linjer E, Scherst�n B, Wester PO, Hedner T, de Faire U. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group.. J Hypertens 2000 Nov;18:1671-5
      Pubmed | Hubmed | Fulltext
    • Hansson L, Lindholm LH, Ekbom T, Dahl�f B, Lanke J, Scherst�n B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.. Lancet 1999;354:1751-6
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend